Valproate May Control JME Better Than Levetiracetam

What was studied

This paper combined results from 7 studies that compared two seizure medicines, valproate (VPA) and levetiracetam (LEV), in people with juvenile myoclonic epilepsy (JME). In total, 1,009 patients were included. The researchers looked for studies with at least 6 months of follow-up and included both randomized trials and observational comparison studies.

They focused mainly on seizure remission and drug failure or treatment discontinuation. They also looked at side effects such as memory impairment, weight gain or obesity, dizziness, and overall adverse effects.

What they found

Across the combined studies, valproate was associated with higher seizure remission rates than levetiracetam, although this result showed substantial variation across studies. People taking valproate were also less likely to have drug failure or stop treatment. At the same time, valproate was associated with more memory impairment and more weight gain or obesity. The two medicines did not show a significant difference for dizziness.

Limits of the evidence

The results are not fully certain. Most of the included studies were observational rather than randomized trials, and the authors identified serious risk of bias in most studies. The seizure remission result also varied a lot across studies, which lowers confidence in that estimate. This review does not show that one medicine is best for every person with JME, and larger randomized trials with longer follow-up are still needed.

For families and caregivers

For families, this review suggests a trade-off. Valproate was associated with better seizure remission and was less likely to be discontinued, but it was also associated with more memory problems and weight gain. The abstract also notes that valproate use can be limited by important adverse effects, including teratogenic risks. This means treatment choices may depend not only on seizure control, but also on side effects and what matters most to the patient and family.

What to watch next

Large randomized studies with longer follow-up and clear, standard ways of measuring seizure control and side effects are needed to better define the risk-benefit profiles of levetiracetam and valproate in JME.

Terms in this summary

juvenile myoclonic epilepsy

A genetic generalized epilepsy syndrome that usually starts in adolescence.

systematic review

A study that carefully collects and summarizes all relevant research on a question.

meta-analysis

A method that combines results from several studies to estimate an overall effect.

seizure remission

A period when seizures stop or are controlled, based on the study's definition.

observational study

A study where researchers observe what happens in real-world treatment, without randomly assigning medicines.

risk ratio

A number that compares how often an outcome happens in one group versus another.

heterogeneity

How different the study results are from each other.

teratogenic

Able to harm a developing baby during pregnancy.